Moderna and Merck's personalized mRNA cancer vaccine cut melanoma recurrence risk by 42%

What happened: Moderna and Merck reported that their personalized mRNA cancer vaccine, given with Keytruda, reduced melanoma recurrence risk by 42%. Key numbers: 42% reduction in melanoma recurrence risk; 38% reduction in risk of distant metastasis or death; overall survival data remain immature. Why it matters: The results support combining the mRNA vaccine with Keytruda in melanoma, though overall survival data are not yet mature. Coverage: 3 outlets in 24h

Moderna and Merck reported that their personalized mRNA cancer vaccine, given with Keytruda, reduced melanoma recurrence risk by 42%.

The results support combining the mRNA vaccine with Keytruda in melanoma, though overall survival data are not yet mature.